CRISPR Therapeutics
CRISPR Therapeutics AG is a Swiss-headquartered, NASDAQ-listed biotech that develops CRISPR/Cas9 gene-editing therapies, including CASGEVY — the first FDA-approved CRISPR-based therapy for sickle cell disease and beta thalassemia, co-commercialized with Vertex Pharmaceuticals across 75+ treatment centers globally.
- Company typePublic
- Founded2013
- HeadquartersCambridge, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What CRISPR Therapeutics does
CRISPR Therapeutics AG is a Swiss-headquartered, NASDAQ-listed (CRSP) clinical-stage-to-commercial biotechnology company founded in 2013 that develops transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. Its foundational product CASGEVY (exagamglogene autotemcel) — co-developed and co-commercialized with Vertex Pharmaceuticals under a 60/40 U.S. profit-share arrangement — is the first CRISPR/Cas9 gene-edited therapy approved by the FDA (December 2023 for sickle cell disease, January 2024 for transfusion-dependent beta thalassemia) and by the European Commission (2024). The product is an autologous ex vivo CRISPR-edited hematopoietic stem cell therapy priced at $2.2 million per patient, distributed through 75+ authorized treatment centers globally via Vertex's specialty pharmacy and sales force.
The company's technology platform spans CRISPR/Cas9 gene editing, an allogeneic CAR-T chassis with multiplexed edits (CTX112 and related programs), the SyNTase gene correction platform (CTX460), in vivo delivery via lipid nanoparticles and AAV vectors (CTX310, CTX320), CRISPR-X next-generation editing modalities, and ex vivo hematopoietic stem cell editing. Pipeline breadth extends to 5 clinical-stage and 10 preclinical-stage programs covering hemoglobinopathies, immuno-oncology, autoimmune diseases (including CTX112/zugo-cel in lupus, scleroderma, and myositis), in vivo cardiovascular (Lp(a) and ANGPTL3 targets), and regenerative medicine (Type 1 diabetes via ViaCyte partnership).
The business model combines CASGEVY product revenue on a 60/40 U.S. profit-share with Vertex (FY2025 revenue $116 million, Q1 2026 $43 million), supplemented by collaboration revenue from milestone/royalty arrangements with partners including Vertex, Sirius Therapeutics, Nkarta, Capsida, and Bayer (Casebia Therapeutics). Customer concentration is high — effectively a single commercial product and a single dominant commercialization partner — though patient end-customer reach is broadening as authorized treatment centers expand across the U.S. and Europe. The company reported a $581.6 million net loss in FY2025 against a $2.44 billion cash position (post-March 2026 convertible raise) that funds ongoing pipeline development.
CRISPR Therapeutics firmographics
Firmographics- Name
- CRISPR Therapeutics
- Legal name
- CRISPR Therapeutics AG
- Website
- https://crisprtx.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- CRISPR Therapeutics AG is a Swiss-headquartered, NASDAQ-listed biotech that develops CRISPR/Cas9 gene-editing therapies, including CASGEVY — the first FDA-approved CRISPR-based therapy for sickle cell disease and beta thalassemia, co-commercialized with Vertex Pharmaceuticals across 75+ treatment centers globally.
- Ownership category
- akta.pro rank
CRISPR Therapeutics industry classification
Industry- Product category
- Gene-Editing Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where CRISPR Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
CRISPR Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- CASGEVY Product Sales: CRISPR Therapeutics co-commercializes CASGEVY with Vertex Pharmaceuticals in the U.S. on a 60/40 profit-share basis. Vertex is the manufacturer and exclusive license holder. Revenue from product sales of the CRISPR-based gene editing therapy for sickle cell disease and beta thalassemia.
- Collaboration Revenue: Revenue from strategic collaborations including milestone payments, royalty payments, and cost-sharing arrangements with partners such as Vertex Pharmaceuticals, Sirius Therapeutics, and others for co-development programs.
- Grant Revenue: Revenue from research grants, including a grant from Friedreich's Ataxia Research Alliance to advance in vivo CRISPR/Cas9 gene editing therapies for HIV.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | CASGEVY (exagamglogene autotemcel) - $2.2 million per patient one-time treatment |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
CRISPR Therapeutics product offering
Product offeringCore offering
CRISPR Therapeutics develops and commercializes CRISPR/Cas9 gene-editing therapies for serious genetic diseases. Its lead approved product, CASGEVY (exagamglogene autotemcel), is the first CRISPR-based gene-editing therapy approved by FDA, MHRA, and EC for sickle cell disease and transfusion-dependent beta thalassemia. The company also advances a diversified pipeline across hemoglobinopathies, immuno-oncology, autoimmune diseases, in vivo cardiovascular, and regenerative medicine.
Differentiator
Problem solved
Functional benefit
Brands
- CASGEVY: First-ever approved CRISPR-based gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, co-developed with Vertex Pharmaceuticals
- SyNTase
- CRISPR-X
Products and services
- CASGEVY (exagamglogene autotemcel) Ex vivo CRISPR/Cas9 gene-edited autologous cell therapy for patients with sickle cell disease and transfusion-dependent beta thalassemia. Administered at authorized treatment centers through Vertex Pharmaceuticals' specialty distribution network at a one-time price of $2.2 million per patient.
Quantifiable outcome
- Over 90% of trial participants achieved functional cure with CASGEVY
- +5 more outcomes
Companies that use CRISPR Therapeutics
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles2 records
CRISPR Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
CRISPR Therapeutics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, minor and flagship.
- Sirius TherapeuticscoreMulti-target collaboration to develop novel siRNA therapies. CRISPR and Sirius announced first patient dosed in Phase 2 trial of SRSD107 for thromboembolic disorders in Europe in September 2025. CTX611 (siRNA targeting FXI) is part of this collaboration.
- Capsida BiotherapeuticsminorStrategic collaboration to develop gene-edited therapies for amyotrophic lateral sclerosis (ALS) and Friedreich's Ataxia using Capsida's in vivo gene editing delivery platform.
- NkartaminorGlobal collaboration to develop gene-edited cell therapies for cancer, combining Nkarta's NK cell platform with CRISPR's gene editing capabilities.
- ViaCytecoreStrategic collaboration to develop gene-edited stem cell-derived therapy for diabetes. First patient dosed in Phase 1 clinical trial in February 2022. Collaboration includes development of immune-evasive cell replacement therapy for Type 1 diabetes.
- Vertex PharmaceuticalsflagshipVertex and CRISPR co-develop and co-commercialize exa-cel (now CASGEVY) for sickle cell disease and beta thalassemia. Vertex is manufacturer and exclusive license holder with 60/40 U.S. profit-share. Collaboration expanded to include Duchenne's Muscular Dystrophy, Myotonic Dystrophy Type 1, and Cystic Fibrosis programs.
- Bayer (Casebia Therapeutics)coreCasebia Therapeutics (Bayer-CRISPR joint venture) focused on developing CRISPR-based therapies for eye, heart, and lung diseases using Bayer's IP and CRISPR's technology.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
CRISPR Therapeutics competitors and assessment
Company assessmentDirect peers
- Intellia Therapeutics: CRISPR/Cas9-based gene editing company developing both in vivo (LNP-delivered, liver-targeted NTLA-2001/2002 for ATTR and HAE) and ex vivo cell therapies. Closely comparable as a co-founder of the original CRISPR IP pool and a direct competitor in hemoglobinopathies, in vivo editing, and gene editing delivery.
- Editas Medicine: CRISPR-based gene editing company developing both Cas9 and Cas12a modalities for sickle cell disease, oncology, and in vivo indications. Shares foundational CRISPR IP with CRISPR Therapeutics and is the most direct competitor in hemoglobinopathies.
- Beam Therapeutics: Pioneer in base editing — a next-generation CRISPR-adjacent modality — with clinical-stage programs in sickle cell disease, alpha-1 antitrypsin deficiency, and other genetic diseases. Directly competes in the same hemoglobinopathy and rare disease gene editing markets.
- Verve Therapeutics: In vivo base editing company focused on cardiovascular disease targeting Lp(a), PCSK9, and ANGPTL3. Closely overlaps with CRSP's CTX310/CTX320 in vivo cardiovascular programs and represents direct competition in the same patient population.
Emerging players
- Prime Medicine: Developer of prime editing, a next-generation CRISPR-derived gene editing modality with applications across rare diseases, oncology, and liver diseases. Competes for similar therapeutic areas and partnership attention from major pharma.
- Caribou Biosciences: CRISPR-based allogeneic CAR T company co-founded by CRISPR co-inventor Jennifer Doudna and a co-holder of foundational CRISPR IP. Partial overlap in allogeneic cell therapy and gene editing platform.
- Tessera Therapeutics: Developer of Gene Writing and other next-generation genome engineering technologies. Emerging competitor in the broader gene editing space with potential overlap in cardiovascular and rare disease indications.
Broad incumbents
- Vertex Pharmaceuticals: CRSP's flagship co-development/co-commercialization partner for CASGEVY (60/40 U.S. profit-share) and holder of exclusive manufacturing/license rights. Both partner and broader incumbent in genetic disease therapeutics (cystic fibrosis franchise).
- Sangamo Therapeutics: Pioneer in genome editing (zinc finger nucleases) with clinical-stage programs in hemoglobinopathies and rare diseases. Operates in the same gene editing category with broader historical footprint but smaller pipeline.
Others
- Nkarta: Allogeneic NK cell therapy company collaborating with CRSP (2021) on gene-edited cell therapies for cancer. Connected through their partnership and shared focus on off-the-shelf engineered cell therapies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights6 records
Customer concentration
CRISPR Therapeutics social profiles
Digital presenceCRISPR Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
CRISPR Therapeutics leadership team
Management profileNumber of profiles
Profiles11 records
CRISPR Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
CRISPR Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CRISPR Therapeutics M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CRISPR Therapeutics
What does CRISPR Therapeutics do?
CRISPR Therapeutics develops and commercializes CRISPR/Cas9 gene-editing therapies for serious genetic diseases. Its lead approved product, CASGEVY (exagamglogene autotemcel), is the first CRISPR-based gene-editing therapy approved by FDA, MHRA, and EC for sickle cell disease and transfusion-dependent beta thalassemia. The company also advances a diversified pipeline across hemoglobinopathies, immuno-oncology, autoimmune diseases, in vivo cardiovascular, and regenerative medicine.
Is CRISPR Therapeutics a public or private company?
CRISPR Therapeutics is a public company. It is classified as public and is currently operating.
When was CRISPR Therapeutics founded?
CRISPR Therapeutics was founded in 2013. It employs 251 to 500 people.
Where is CRISPR Therapeutics based?
CRISPR Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does CRISPR Therapeutics make money?
Three revenue lines are on record. CASGEVY Product Sales are the primary driver. The others are collaboration Revenue and grant Revenue.
Who are CRISPR Therapeutics's main competitors?
Direct peers on record are Intellia Therapeutics, Editas Medicine, Beam Therapeutics and Verve Therapeutics. Emerging players are Prime Medicine, Caribou Biosciences and Tessera Therapeutics. Broad incumbents are Vertex Pharmaceuticals and Sangamo Therapeutics. Nkarta is listed as an others.
Does CRISPR Therapeutics have an API?
No public API is recorded for CRISPR Therapeutics.
What industry is CRISPR Therapeutics in?
CRISPR Therapeutics's product category is Gene-Editing Therapeutics. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 325414 and its SIC code is 2834.